Within the last decade, the WHO grading system of gliomas that is historically based upon histopathologic markers of malignancy has been significantly altered and augmented by use of molecular alterations like isocitrate dehydrogenase (IDH)-1/2-mutation [5]. Here, IDH1 is linked to central nervous system cancer.